Are we Bypassing the Biomarker Experts?

NGS has transformed GU cancer treatment.

Pathologists must oversee molecular testing.

There are significant workflow barriers in GU pathology.

Urine-based tests show potential but require validation.

Direct marketing to oncologists bypasses pathologists.

Collaboration is essential for effective patient care.

Test duplication can affect costs and outcomes.